TAK Takeda Pharmaceutical Company: Net earnings per share growth forecast for next year

Official company branding of Takeda Pharmaceutical (TAK)

Steady demand for orphan disease therapies guarantees Takeda Pharmaceutical (TAK) a stable cash flow. The expected change in net profit reflects the real-time valuation, where the parameter value equals 57.40. The Japanese pharma market leader relies on the plasma and gastroenterology segments to maintain margins, while outsourcing testing and logistics to external partners accelerates the business's global expansion.

TAK: Takeda Pharma Net earnings per one share growth forecast for next year 07/04/2022 - 11/16/2026

Analytical breakdowns and data insights for company Takeda Pharmaceutical Company (TAK)

- share price and consensus valuation forecast:
- company stock capitalization data:
Basic company analysis:Takeda Pharmaceutical Company, TAK
Finished products of Takeda

When assessing the asset quality of Takeda Pharmaceutical (TAK), we focus on the resilience of its fundamental indicators. The projected EPS growth rate for next year on GURU.Markets measures the expected earnings per share dynamics, revealing the gap between market expectations and the business's actual trajectory. For Takeda Pharmaceutical, this indicator confirms the stability of revenues from global oncology drug sales. Any deviation from these forecasts signals risks to capital.